Osteosarcoma (OS)
Overview
Osteosarcoma is a primary malignant bone tumor classified under BONE in the OncoTree hierarchy. It can arise sporadically or as a radiation-associated sarcoma.
Cohorts in the corpus
- sarcoma_msk_2023: 12 RT-osteosarcoma patients and 76 sporadic osteosarcoma controls, sequenced on MSK-IMPACT PMID:37350195.
Recurrent alterations
- TP53 LOF mutations/deletions in 42% of RT-OS vs 14% sporadic OS PMID:37350195.
- CDKN2A/CDKN2B deletions in 33% of RT-OS PMID:37350195.
- PTEN truncating mutations/deletions in 17% of RT-OS vs 14% sporadic OS PMID:37350195.
- FGFR1 amplification in 17% of RT-OS vs 7% sporadic OS PMID:37350195.
- PTPRT missense mutations in 17% of RT-OS vs 7% sporadic OS PMID:37350195.
- FGA of 32% in RT-OS PMID:37350195.
- Translocations were more frequent in RT-OS (and RT-MPNST) compared to other RT-sarcoma histotypes PMID:37350195.
- PIPseq cohort identified TSC1 splice-site c.2503-1G>C (mTOR-inhibitor target), RAD51C F8L (PARP-inhibitor target), PDGFRA/KDR overexpression (MTKI treated), MYC/MCL1/CCNE1 overexpression (BET- and CDK4/6 targets), CUL4A overexpression (NAE-inhibitor target), RB1 splice-site c.1216-3A>G (germline, increased second-cancer risk), and TNNT2 R141Q (ACMG secondary, dilated cardiomyopathy) in osteosarcoma patients PMID:28007021
- Germline WES of 372 pediatric cancer patients (Düsseldorf) included osteosarcoma cases; TP53 LP/PV carriers (Li-Fraumeni syndrome) presented with osteosarcoma; three of six TP53 carriers (50%) developed SMNs including one osteosarcoma patient PMID:29489754
Subtypes
- Radiation-associated osteosarcoma (RT-OS): Higher TP53 alteration rate (42% vs 14%) and enrichment for FGFR1 and PTPRT alterations compared to sporadic OS. Median latency from radiation: 9.0 years PMID:37350195.
- Sporadic osteosarcoma: Lower TP53 alteration frequency (14%) and similar PTEN rates PMID:37350195.
Therapeutic landscape
- Genomic profiling supports histotype-specific treatment; RT-OS shows distinct alterations (FGFR1 amplification, PTPRT mutations) that may represent therapeutic targets PMID:37350195.
Sources
- PMID:37350195 — Dermawan JK et al., J Pathol 2023. Comparative genomic analysis of 82 RT-sarcomas including 12 RT-osteosarcomas.
This page was processed by crosslinker on 2026-04-11. - PMID:28007021
This page was processed by wiki-cli on 2026-05-14. - PMID:29489754
This page was processed by wiki-cli on 2026-05-15.